Minerva Neurosciences | NERV - Gross Profit On Sales


Minerva Neurosciences reported -4.27M in Gross Profit on Sales for its fiscal quarter ending in December of 2024.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Adma Biologics USD 80.75M 8.07M Mar/2026
ALKERMES USD 375.31M 43.98M Jun/2026
AstraZeneca USD 12.86B 251M Jun/2026
BioCryst Pharmaceuticals USD 214.41M 61.36M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Cipla INR 44.1B 5B Jun/2026
Clal Biotechnology ILS -857K 1.42M Jun/2022
Compugen USD 352K 63.44M Mar/2026
CSL USD 4.46B 2.71B Dec/2025
Eli Lilly USD 16.22B 301.7M Mar/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
Grifols EUR 766.49M 39.74M Dec/2024
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
J&J USD 18.55B 1.31B Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Minerva Neurosciences -4.27M 26.79M Dec/2024
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Novavax USD 125.04M 76.09M Dec/2025
Pfizer USD -248M 11.29B Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sanofi EUR 8.71B 602M Jun/2026
Takeda JPY 813.22B 124.39B Jun/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024